Search Result
Results for "
Synergistic activities
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-164460
-
|
|
Pim
|
Cancer
|
|
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways .
|
-
-
- HY-A0241
-
|
RP54476
|
Antibiotic
Bacterial
|
Infection
|
|
Dalfopristin (RP54476) is a semisynthetic sulfone antibiotic. Dalfopristin alone has limited antibacterial activity, but synergistically with Quinupristin it has significant bactericidal activity against many pathogenic Gram-positive cocci .
|
-
-
- HY-B0901A
-
|
R-11333 hydrochloride
|
Dopamine Receptor
Bacterial
|
Neurological Disease
|
|
Bromperidol (R-11333) hydrochloride possesses antipsychotic activity, with a high affinity for central dopamine receptors D2. Bromperidol hydrochloride can kill Mycobacteria in a synergistic manner with Spectinomycin .
|
-
-
- HY-B0901
-
-
-
- HY-173163
-
|
|
Bacterial
|
Infection
|
|
(E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) (Compound 4a) is a Gram-negative outer membrane permeabilizer with synergistic antibacterial activity through the blockage on LptA/LptC interaction via targeting Met47 in LptA. (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) potentiates pol B against both wild-typed and MDR A. baumannii and E. coli strains. (E)-2,6-Di-tert-butyl-4-(4-(diethylamino)styryl)pyrylium (trifluoromethanesulfonate) can be used as antibiotic adjuvants against MDR Gram-negative bacteria .
|
-
-
- HY-143414
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
|
-
-
- HY-175724
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
MBL-IN-6 (Compound 6d) is a Metallo-β-lactamase (MBL) inhibitor with Kis of 2.6 and 0.08 μM for NDM-1 and VIM-2, respectively. MBL-IN-6 has a synergistic activities with Imipenem (HY-B1369A) on MBL-producing clinical isolates (such as E. coli SI-M001, K. pneumonia T2301 and S. marcescens SI-1591) with MICs of 2-64 μg/mL. MBL-IN-6 does not have off-target effects without ACE-1 inhibition activity. MBL-IN-6 can be used for antimicrobial resistance research .
|
-
-
- HY-165117
-
|
|
Others
|
Others
|
|
Bactobolamine is an immunosuppressive compound that has synergistic activity with cyclosporine in inhibiting allogeneic lymphocyte activation in vitro.
|
-
-
- HY-162163
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7 agonist 19 (Compound 14) is a Toll-like receptor 7 (TLR7) agonist with excellent pharmacokinetic properties and synergistic antitumor activity.
|
-
-
- HY-A0241A
-
|
RP54476 mesylate
|
Antibiotic
Bacterial
|
Infection
|
|
Dalfopristin (RP54476) mesylate is a semisynthetic sulfone antibiotic. Dalfopristin mesylate alone has limited antibacterial activity, but synergistically with Quinupristin it has significant bactericidal activity against many pathogenic Gram-positive cocci .
|
-
-
- HY-161870
-
|
|
Antibiotic
|
Infection
|
|
Antibiotic adjuvant 1 (compound 3e) is an antibiotic adjuvant that presents insufficient antibacterial activity (MIC > 128 µg/mL) and potentiate the activity of Cloxacillin (HY-B0466A)(66-fold) with synergistic effect .
|
-
-
- HY-153731
-
|
|
Deubiquitinase
|
Cancer
|
|
USP1-IN-4 (compound 10) is an effective USP1 inhibitor with an IC50 value of 2.44 nM. USP1-IN-4 has anticancer activity and synergistic activity with various anticancer drugs .
|
-
-
- HY-122289
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
|
|
Metioprim is a competitive inhibitor of bacterial Dihydrofolate reductase (DHFR). Metioprim has inhibitory activity against anaerobic bacteria. Metioprim shows synergistic activity in combination with DDS (HY-B0688) against E. coli. and various mycobacteria .
|
-
-
- HY-163070
-
|
|
Parasite
|
Infection
|
|
Antimalarial agent 35 (compound QP11) is a selective inhibitor FP2. Antimalarial agent 35 has antimalarial activity and shows synergistic effects when combined with chloroquine(HY-17589A) .
|
-
-
- HY-129329
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Lankamycin, a macrolide antibiotic, shows moderate antimicrobial activity against several gram-positive bacteria, acting as a synergistic pair with carbocyclic antibiotic Lankacidin C (HY-121412) by binding to the ribosome exit tunnel .
|
-
-
- HY-160409
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .
|
-
-
- HY-130079
-
|
Penicillin G procaine
|
Bacterial
|
Infection
|
|
Procaine benzylpenicillin (Penicillin G procaine) is an antimicrobial agent. Procaine benzylpenicillin shows inhibitory activity against gram-positive bacteria and synergistic activity with Neomycin (HY-B0470). Procaine benzylpenicillin can be used in the study of bovine mastitis in animal husbandry .
|
-
-
- HY-106892
-
|
348U87
|
DNA/RNA Synthesis
|
Infection
|
|
BW 348U87 is an inhibitor for ribonucleotide reductase, which exhibits synergistic effect with Acyclovir (HY-17422), potentiate the antiviral activity of Acyclovir against herpes simplex virus (HSV) in athymic nude mouse model .
|
-
-
- HY-163191
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1 inhibitor-5 (compound 57) is a potent NDM-1 inhibitor, with a Ki of 2.5 μM. NDM-1 inhibitor-5 also shows antibacterial synergistic activity with meropenem (HY-13678) .
|
-
-
- HY-B0901R
-
|
R-11333 (Standard)
|
Reference Standards
Dopamine Receptor
Bacterial
|
Infection
Neurological Disease
|
|
Bromperidol (Standard) is the analytical standard of Bromperidol. This product is intended for research and analytical applications. Bromperidol (R-11333) possesses antipsychotic activity, with a high affinity for central dopamine receptors D2. Bromperidol can kill Mycobacteria in a synergistic manner with Spectinomycin .
|
-
-
- HY-150583
-
|
|
Fungal
Antibiotic
|
Inflammation/Immunology
|
|
Chitin synthase inhibitor 2 (compound 2b) is a potent inhibitor of chitin synthase with the IC50 value of 0.09 mM and the Ki value of 0.12 mM. Chitin synthase inhibitor 2 has antimicrobial activities in vitro and shows synergistic or additive effects with fluconazole or polyoxin B .
|
-
-
- HY-N14918
-
|
|
Bacterial
|
Infection
|
|
N-(2,6-Diamino-6-hydroxymethylpimelyl)-L-alanine shows anti-Escherichia coli activity, and is combined with several cell wall synthesis inhibitors such as Fosfomycin, Cycloserine, Penicillin, and Cephalosporin, the combination of sporozoin has obvious synergistic antibacterial effect .
|
-
-
- HY-30270
-
|
p-Hydroxyanisole
|
HSP
Estrogen Receptor/ERR
|
Endocrinology
|
|
Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .
|
-
-
- HY-157937
-
|
|
IFNAR
|
Cancer
|
|
VISTA-IN-3 (Compound A4) is a potent VISTA small molecule inhibitor with a KD value of 0.49 μM. VISTA-IN-3 can induce the release of IFN-γ cytokines. VISTA-IN-3 synergistically enhances anti-cancer activity with PD-L1 antibody .
|
-
-
- HY-118911
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active ATM inhibitor (IC50: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .
|
-
-
- HY-164413
-
|
|
VEGFR
EGFR
RET
Apoptosis
|
Cancer
|
|
CLM3, a pyrazolopyrimidine derivative, is a multiple tyrosine kinase inhibitor. CLM3 shows antiproliferative and proapoptotic activity on endothelial and cancer cells, synergistically enhanced by SN38 (HY-13704). These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signaling pathways .
|
-
-
- HY-143415
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-7 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.019 μM, 13.64 μM, 0.38 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-7 potentiate antibacterial activity of Meropenem against the Gram-negative bacterial strains .
|
-
-
- HY-169224
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
|
-
-
- HY-W141881
-
|
|
Biochemical Assay Reagents
HSV
|
Infection
|
|
N-lauroylsarcosine is an anionic surfactant. N-lauroylsarcosine has antiviral activity against HSV-2 strain 333 and HSV-1 strain F. N-lauroylsarcosine synergistically increases skin permeability with 25-50% ethanol. N-lauroylsarcosine can be used to study HSV-2 infection .
|
-
-
- HY-146078
-
|
|
Bacterial
|
Infection
|
|
Antimicrobial agent-1 (compound 6C) possesses potent activity against TolC mutant E. coli with an MIC value of 2 μg/mL. Antimicrobial agent-1 and Colistin exhibit synergistic activity against Gram-negative bacteria. Antimicrobial agent-1 has no cytotoxicity on mammalian cell lines, with MICs > 128 μg/mL in Caco-2 and Vero cell lines .
|
-
-
- HY-155248
-
|
|
HDAC
|
Cancer
|
|
HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) .
|
-
-
- HY-144659
-
|
|
Beta-lactamase
Apoptosis
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
|
-
-
- HY-146565
-
|
|
DNA-PK
|
Cancer
|
|
DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .
|
-
-
- HY-139855
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Metabolic Disease
|
|
ZG-2033 (Compound 26) is an orally active HIF-2α agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC50 = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .
|
-
-
- HY-161516
-
|
|
HDAC
|
Cancer
|
|
HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC50=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research .
|
-
-
- HY-112665
-
|
Streptogramin; Mikamycin; RP 7293
|
Antibiotic
Bacterial
|
Infection
|
|
Virginiamycin Complex (Streptogramin) is an antibiotic containing two streptogramins, virginiamycin M (VM) and virginiamycin S (VS), which are produced by S. virginiae. As a complex, these two antibiotics in Virginiamycin Complex act synergistically. The action of VM is persistent and catalytic, and it can alter the affinity of ribosomes for VS. Virginiamycin Complex irreversibly inhibits protein synthesis in bacteria and has antibacterial activity .
|
-
-
- HY-167715
-
|
|
Histamine Receptor
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro.
Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase
activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
|
-
-
- HY-161765
-
|
|
HSP
STAT
|
Cancer
|
|
iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
|
-
-
- HY-30270R
-
|
p-Hydroxyanisole (Standard)
|
HSP
Estrogen Receptor/ERR
Reference Standards
|
Endocrinology
|
|
Mequinol (Standard) is the analytical standard of Mequinol. This product is intended for research and analytical applications. Mequinol (4-Methoxyphenol)yes MercurialisOne of the bioactive ingredients, mainly used for skin discoloration . MequinolIs an antioxidant that has additive/synergistic effects on carcinogenesis when combined with other phenolic antioxidants. Mequinolalso promote hERαDependent chaperone production with potential estrogenic activity .
|
-
-
- HY-149333
-
|
|
Bacterial
|
Infection
|
|
BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
|
-
-
- HY-122639
-
|
|
NEKs
|
Cancer
|
|
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .
|
-
-
- HY-143236
-
|
|
Bacterial
Fungal
|
Infection
|
|
DHFR-IN-1 (compound 12) is a potent and selective DHFR (dihydrofolate reductase)inhibitor, with an IC50 of 40.71 nM. DHFR-IN-1 exhibits promising antibacterial activity against gram-positive and gram-negative bacteria. DHFR-IN-1 exhibits moderate antifungal activities. DHFR-IN-1 exhibits a high synergistic effect with Levofloxacin (HY-B0330), where the FIC (fractional inhibitory concentration index) value is 0.249 .
|
-
-
- HY-170649
-
|
|
SARS-CoV
|
Infection
|
|
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
|
-
-
- HY-147310
-
|
|
Toll-like Receptor (TLR)
|
Infection
|
|
CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .
|
-
-
- HY-Y0958
-
|
O-Methylhydroxylamine hydrochloride
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Methoxyamine (O-Methylhydroxylamine) hydrochloride is an orally active and potent base excision repair (BER) inhibitor. Methoxyamine hydrochloride binds to 3’ hydroxyl groups that are left behind by 3-methylpurine-DNA glycosylase (MPG) following excision of the damaged base and thus inhibits BER activity. Methoxyamine hydrochloride binds directly to the apyrimidinic (AP) sites. Methoxyamine hydrochloride synergistically enhances the therapeutic efficacy of DNA-damaging agents .
|
-
-
- HY-169407
-
|
|
Akt
mTOR
MEK
ERK
Apoptosis
|
Cancer
|
|
KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib (HY-10999) .
|
-
-
- HY-149881
-
|
|
Bacterial
|
Infection
|
|
Quorum sensing-IN-2 (compound 23e) is a quorum sensing inhibitor, which can reduce the pathogenicity of bacteria without affecting bacterial growth. Quorum sensing-IN-2 inhibits bacterial infections with little hemolytic activity. Quorum sensing-IN-2 shows synergistic effect with Ciprofloxacin (HY-B0356) in the bacteremia model infected with P. aeruginosa PAO1 .
|
-
-
- HY-128355A
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Others
Cancer
|
|
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .
|
-
-
- HY-156090
-
|
|
Mitochondrial Metabolism
Fungal
|
Infection
|
|
PK-10 is a synergistic antibacterial agent of Fluconazole (HY-B0101) and has strong antifungal activity against a variety of Fluconazole-resistant Candida albicans strains. PK-10 combined with Fluconazole can inhibit hyphae formation and induce the accumulation of reactive oxygen species. It further causes damage to mitochondrial membrane potential, reduces intracellular ATP content, and leads to mitochondrial dysfunction .
|
-
-
- HY-161152
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
DNA relaxation-IN-1 (Compound 27) is a DNA ligase 1 DNA Lig1) inhibitor. DNA relaxation-IN-1 inhibits DNA ligation and disrupts the DNA relaxing activity of DNA Lig1. DNA relaxation-IN-1 induces Apoptosis. DNA relaxation-IN-1, in combination with Topotecan (HY-13768), exhibits synergistic antiproliferative effects against colorectal cancer .
|
-
- HY-W134005
-
|
Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate
|
Phosphatase
|
Others
|
|
Mg(Ⅱ)-EDTA disodium tetrahydrate is a reversible non-covalent activator of fructose diphosphatase (Km=0.9 μM). Mg(Ⅱ)-EDTA disodium tetrahydrate synergistically activates fructose diphosphatase with free Mg 2+, promotes the hydrolysis of fructose-1,6-bisphosphate at pH≤8, and plays a role in enhancing the activity of key enzymes in gluconeogenesis .
|
-
- HY-108531
-
|
|
RAR/RXR
|
Metabolic Disease
|
|
ER 50891 is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis .
|
-
- HY-108531A
-
|
|
RAR/RXR
|
Cancer
|
|
ER 50891 quarterhydrate is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis .
|
-
- HY-P5589
-
|
PlnA
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
Inflammation/Immunology
|
|
Plantaricin A is an antimicrobial peptide that can be derived from Lactobacillus plantarum. Plantaricin A has a synergistic effect with Ciprofloxacin. Plantaricin A shows anti-microbial activity. Plantaricin A increases the membrane potential of S. aureus and the level of intracellular ROS. Plantaricin A inhibits the function of the efflux pump by binding it and altering the structure of MepA, NorA, and LmrS. Plantaricin A significantly relieves inflammation, and promotes wound healing. Plantaricin A permeabilizes cancerous rat pituitary cells [1][2].
|
-
- HY-P4032
-
|
|
HCV
|
Inflammation/Immunology
|
|
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
|
-
- HY-146112
-
|
|
IRAK
|
Cancer
|
|
IRAK4-IN-14 (compound 28) is a potent, selective and orally active IRAK4 inhibitor with an IC50 of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .
|
-
- HY-161356
-
|
|
SARS-CoV
|
Infection
|
|
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .
|
-
- HY-144338
-
|
|
Epigenetic Reader Domain
PARP
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
PARP1/BRD4-IN-1 is a potent and high selective PARP1/BRD4 inhibitor (IC50s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .
|
-
- HY-146113
-
|
|
IRAK
|
Cancer
|
|
IRAK4-IN-15 (compound 35) is a potent and selective IRAK4 inhibitor with an IC50 of 0.002 µM. IRAK4-IN-15 shows good human PK predictions with low intrinsic clearance. IRAK4-IN-15 shows great synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib. .
|
-
- HY-172874
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
|
-
- HY-164492
-
|
|
Raf
|
Cancer
|
|
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .
|
-
- HY-150090
-
|
|
CFTR
|
Inflammation/Immunology
|
|
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity .
|
-
- HY-N7135
-
|
|
Tyrosinase
Fungal
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU 2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
|
-
- HY-168861
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1 inhibitor-8 (Compound 18b) is the covalent inhibitor for new delhi metallo-β-lactamase-1 (NDM-1) with an IC50 of 7.03 μM. NDM-1 inhibitor-8 inhibits the drug resistant strains, exhibits synergistic antibacterial effect with the use of Meropenem (HY-13678). NDM-1 inhibitor-8 exhibits anti-infectious activity in mouse models .
|
-
- HY-W014130
-
|
Ac-Arg-OH
|
Endogenous Metabolite
|
Others
|
|
N-Acetyl-L-arginine (Ac-Arg-OH) is one of the guanidino compounds found elevated in the serum of a hemodialyzed renal insufficient (uremic) pediatric population. N-Acetyl-L-arginine shows synergistic activity with glycine buffer. N-Acetyl-L-arginine suppresses the aggregation of intravenous immunoglobulins with a minimum decrease in transition temperature. N-Acetyl-L-arginine dramatically reduces IL-1 expression in the presence of silicone oil. N-Acetyl-L-arginine also demonstrates colloidal stability .
|
-
- HY-P99100
-
|
CTL-002
|
TGF-beta/Smad
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-N7135R
-
|
|
Tyrosinase
Fungal
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
|
-
- HY-Y0958R
-
|
O-Methylhydroxylamine hydrochloride (Standard)
|
Reference Standards
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Methoxyamine (hydrochloride) (Standard) is the analytical standard of Methoxyamine (hydrochloride). This product is intended for research and analytical applications. Methoxyamine (O-Methylhydroxylamine) hydrochloride is an orally active and potent base excision repair (BER) inhibitor. Methoxyamine hydrochloride binds to 3’ hydroxyl groups that are left behind by 3-methylpurine-DNA glycosylase (MPG) following excision of the damaged base and thus inhibits BER activity. Methoxyamine hydrochloride binds directly to the apyrimidinic (AP) sites. Methoxyamine hydrochloride synergistically enhances the therapeutic efficacy of DNA-damaging agents .
|
-
- HY-134914
-
|
|
Antibiotic
Parasite
|
Infection
|
|
Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC50s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model .
|
-
- HY-163479
-
|
|
Eukaryotic Initiation Factor (eIF)
MNK
|
Cancer
|
|
MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970) .
|
-
- HY-W014130R
-
|
|
Endogenous Metabolite
|
Others
|
|
N-Acetyl-L-arginine (Ac-Arg-OH) is one of the guanidino compounds found elevated in the serum of a hemodialyzed renal insufficient (uremic) pediatric population. N-Acetyl-L-arginine shows synergistic activity with glycine buffer. N-Acetyl-L-arginine suppresses the aggregation of intravenous immunoglobulins with a minimum decrease in transition temperature. N-Acetyl-L-arginine dramatically reduces IL-1 expression in the presence of silicone oil. N-Acetyl-L-arginine also demonstrates colloidal stability .
|
-
- HY-172970
-
|
|
CDK
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .
|
-
- HY-19476
-
|
|
Virus Protease
|
Infection
|
|
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus .
|
-
- HY-115464
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
NC1153 is a Mannich base with the activity to block IL-2-induced JAK3 activation and its downstream substrate STAT5a/b. NC1153 effectively prolongs the survival of kidney transplants in MHC/non-MHC mismatched rats. NC1153 promotes long-term graft survival and includes multiple toxicity protection for recipients. NC1153 combined with cyclosporine A (CsA) can synergistically prolong graft survival without producing nephrotoxicity, myelotoxicity or lipotoxicity .
|
-
- HY-P99100A
-
|
CLT-002 (Powder)
|
TGF-beta/Smad
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-155198
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 72 (Compound B8) is a potent antifungal agent. Antifungal agent 72 suppresses the function of efflux pump and down-regulates the resistance-associated genes through blocking the Pdr1-KIX interaction (Ki: 11.7 μM). Antifungal agent 72 is active against Fluconazole (HY-B0101)-resistant with a MIC value of 63 ng/mL, and shows synergistic inhibitory activity with Fluconazole. Antifungal agent 72 can be used for C. glabrata infection research .
|
-
- HY-118013
-
|
|
Bacterial
|
Infection
|
|
NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced .
|
-
- HY-116633
-
|
|
Endogenous Metabolite
|
Infection
|
|
BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .
|
-
- HY-164117
-
BNN6
1 Publications Verification
|
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
BNN6 is a thermoresponsive nitric oxide (NO) donor that often works by binding to a carrier. BNN6 decomposes under the heat stimulation generated by photothermal action, releasing high concentrations of NO, which exerts anti-tumor activity by inducing tumor cell apoptosis and inhibiting their repair. BNN6 can be used to synthesize the multifunctional biosensor BNN6-BiTiS3-iRGD, which exerts a synergistic anti-cancer effect with photothermal therapy (PTT) .
|
-
- HY-112665R
-
|
Streptogramin (Standard); Mikamycin (Standard); RP 7293 (Standard)
|
Reference Standards
Antibiotic
Bacterial
|
Infection
|
|
Virginiamycin Complex (Standard) (Streptogramin (Standard)) is the analytical standard of Virginiamycin Complex (HY-112665). This product is intended for research and analytical applications. Virginiamycin Complex (Streptogramin) is an antibiotic containing two streptogramins, virginiamycin M (VM) and virginiamycin S (VS), which are produced by S. virginiae. As a complex, these two antibiotics in Virginiamycin Complex act synergistically. The action of VM is persistent and catalytic, and it can alter the affinity of ribosomes for VS. Virginiamycin Complex irreversibly inhibits protein synthesis in bacteria and has antibacterial activity .
|
-
- HY-103019
-
|
(+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
|
Drug Isomer
CDK
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
(+)-Enitociclib ((+)-BAY-1251152) is the enantiomer of Enitociclib (HY-103019E) with (+) optical rotation. Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
|
-
- HY-12403A
-
|
TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-103019A
-
|
(±)-BAY-1251152; (±)-VIP152
|
CDK
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
|
-
- HY-103019B
-
|
(R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152
|
Drug Isomer
CDK
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
|
-
- HY-175646
-
|
|
Acyltransferase
mTOR
Ribosomal S6 Kinase (RSK)
Apoptosis
|
Cancer
|
|
AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models .
|
-
- HY-134809A
-
|
CADA hydrochloride
|
HIV
|
Infection
|
|
Cyclotriazadisulfonamide (CADA) hydrochloride is a specific CD4-targeted HIV entry inhibitor with activity against HIV-1 replication. Cyclotriazadisulfonamide hydrochloride can specifically downregulate the expression of CD4 receptors on the cell surface, effectively inhibiting HIV transmission. Cyclotriazadisulfonamide hydrochloride can inhibit HIV-1(NL4.3) and SIV(mac251), and has a synergistic effect when used in combination with cellulose acetate (CAP). Cyclotriazadisulfonamide hydrochloride can also be used as a microbial gel formulation to maintain CD4 downregulation and antiviral activity, and is a broad-spectrum anti-HIV agent.
|
-
- HY-12403
-
Talfirastide
Maximum Cited Publications
12 Publications Verification
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-118931
-
|
|
GABA Receptor
|
Neurological Disease
|
|
EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .
|
-
- HY-162642
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bfl-1-IN-3 (Compound 56) is a selective, competitive inhibitor for Bfl-1 on BID binding site with Ki of 105 nM. Bfl-1-IN-3 inhibits the proliferation of cell pfeiffer and MV4-11, with IC50 of 6.92 μM and 12.6 μM. Bfl-1-IN-3 induces apoptosis in pfeiffer cells. Bfl-1-IN-3 overcomes Venetoclax (HY-15531) resistance at the cellular level, and shows synergistically enhanced anti-tumor activity with Venetoclax .
|
-
- HY-P991510
-
|
|
TNF Receptor
|
Cancer
|
|
CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
|
-
- HY-159585
-
|
|
Cytochrome P450
Fungal
|
Infection
|
|
CYP51-IN-20 (compound 5b) is an inhibitor of CYP51 and has antifungal activity. CYP51-IN-20 has a significant inhibitory effect on Candida albicans ATCC 10231, downregulates ERG11 (Cyp51) gene expression, and significantly reduces the yeast-to-hyphae morphological transition. CYP51-IN-20 can synergize with Voriconazole (HY-76200) to occupy the entire CYP51 binding site and exert a synergistic inhibitory effect in the Glechoma moth model .
|
-
- HY-12403R
-
|
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-162492
-
|
|
Influenza Virus
|
Infection
|
|
Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
|
-
- HY-134816
-
|
|
Toll-like Receptor (TLR)
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .
|
-
- HY-P11040
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Peptide P2.2, a non-ribosomal peptide, is an antimicrobial peptide. Peptide P2.2 has potent antibacterial activity with MIC50s of 4 and 32 μM for V. parahaemolyticus and V. alginolyticus, respectively. Peptide P2.2 increases synergistic antibacterial effects with antibiotics (such as Ofloxacin (HY-B0125) and Linezolid (HY-10394)) with negligible hemolytic activity. Peptide P2.2 disrupts bacterial membranes and increases permeability by modulating proteins involved in the type VI and III secretion systems. Peptide P2.2 can be used for bacterial infections research .
|
-
- HY-145931
-
|
|
mTOR
Autophagy
|
Cancer
|
|
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .
|
-
- HY-N1934
-
|
|
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
- HY-149155
-
|
|
Bacterial
|
Infection
|
|
o-Cymen-5-ol is a broad-spectrum antimicrobial agent with direct antimicrobial activity. o-Cymen-5-ol showed effective minimum inhibitory concentrations (MICs) against a variety of bacteria and fungi, such as Streptococcus mutans and Candida albicans. The combination of o-Cymen-5-ol and zinc showed synergistic effects, enhancing the inhibitory effect against oral pathogens. o-Cymen-5-ol was able to inhibit the glycolysis process and co-enhanced this effect with zinc. o-Cymen-5-ol showed a stronger antibacterial effect in toothpaste than placebo .
|
-
- HY-116973
-
|
|
HIV
|
Infection
|
|
L-738372 is a non-competitive reversible inhibitor of HIV-1 reverse transcriptase (RT) with an inhibition constant (Ki) of 140 nM against dTTP. When combined with any nucleoside analogs (such as azidothymidine triphosphate, didexoyinosine triphosphate, or didexoycytidine triphosphate), L-738372 exhibits synergistic inhibition of RT activity. L-738372 has 2-3 times more inhibitory potency against the azidothymidine-resistant RT (D67N, K70R, T215Y, K219Q) compared to the wild-type RT. L-738372 holds promise for research in the field of HIV virus treatment .
|
-
- HY-173437
-
|
|
PROTACs
PARP
DNA/RNA Synthesis
|
Cancer
|
|
CW-2 is a PARP1 PROTAC degrader. CW-2 has potent antiproliferative effects against MDA-MB-231 cells (IC50 = 0.72 μM) and CDDP-resistant cells (A549/CDDP: IC50 = 3.52 μM). CW-2 has synergistic antitumor activity and enhanced membrane permeability. CW-2 exerts antitumor effects by inducing DNA damage, impairing DNA repair, and activating mitochondria-dependent apoptosis (Pink: PARP1 ligand (HY-173441); Blue: E3 CRBN ligand (HY-173439); Black: linker (HY-173440)) .
|
-
- HY-155811
-
|
|
iGluR
|
Neurological Disease
|
|
DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .
|
-
- HY-147245
-
|
STP1002
|
PARP
|
Cancer
|
|
Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
|
-
- HY-174221
-
|
|
IMPDH
HDAC
Apoptosis
|
Cancer
|
|
IMPDH II/HDAC1-IN-1 (Compound C12) is an orally active dual-target inhibitor of IMPDH II and IMPDH II (IC50 values are 84.69 nM and 81.75 nM, respectively). IMPDH II/HDAC1-IN-1 has significant anti-tumor activity and has an anti-proliferative effect on K-562 cells (IC50 = 305.31 nM). IMPDH II/HDAC1-IN-1 exerts a synergistic anti-tumor effect by simultaneously targeting IMPDH II and HDAC1, inhibiting tumor cell proliferation and inducing apoptosis. IMPDH II/HDAC1-IN-1 can be used in the study of cancers such as chronic myeloid leukemia (CML) .
|
-
- HY-N1934R
-
|
|
Reference Standards
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
- HY-167854
-
|
|
Aurora Kinase
Apoptosis
IGF-1R
|
Cancer
|
|
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.
|
-
- HY-159905
-
|
|
MAP4K
|
Inflammation/Immunology
|
|
HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy .
|
-
- HY-176798
-
|
|
Lactate Dehydrogenase
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
|
-
- HY-172892
-
|
|
PI3K
Reactive Oxygen Species (ROS)
|
Cancer
|
|
PI3K-IN-59 (Compound 3d) is a PI3K inhibitor (IC50: 17.44 μM). PI3K-IN-59 has significant antiproliferative activity and exhibits potent inhibitory effects on breast cancer 4T1 cells (IC50: 3.70 μM) and colon cancer CT26 cells (IC50: 1.98 μM) as well as human breast cancer cells (IC50: 19.72 μM). PI3K-IN-59 exerts a dual anti-tumor mechanism by inhibiting PI3Kα enzymatic activity and triggering the Fenton reaction to generate hydroxyl radicals (•OH). PI3K-IN-59 shows promising anti-4T1 tumor effects and is suitable for synergistic targeting studies in breast and colon cancers .
|
-
- HY-N7368
-
|
|
Adenosine Deaminase
Bacterial
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (Ki = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC50 = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .
|
-
- HY-174301
-
|
|
Deubiquitinase
DNA Methyltransferase
MDM-2/p53
|
Cancer
|
|
USP7-IN-18 is a naphthalene derivative. USP7-IN-18 is a selective USP7 inhibitor (IC50 : 130.9 nM), with no or very weak inhibition of the other 8 DUBs including USP47. USP7-IN-18 specifically binds to the catalytic domain of USP7, blocking its deubiquitinase activity. USP7-IN-18 causes degradation of the oncogenic proteins MDM2 and DNMT1, and also degrades the novel target PCLAF. USP7-IN-18 activates the p53-p21 pathway. USP7-IN-18 exerts anti-tumor effects in colon cancer animal models and reshapes the tumor immune microenvironment. USP7-IN-18 achieves both direct cytotoxic and immune-synergistic anti-tumor actions.
|
-
- HY-N7368R
-
|
|
Reference Standards
Adenosine Deaminase
Bacterial
Caspase
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Hibifolin (Standard) is the analytical standard of Hibifolin. This product is intended for research and analytical applications. Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (Ki = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC50 = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .
|
-
- HY-176220
-
|
|
AUTACs
Autophagy
Glutathione Peroxidase
Ferroptosis
|
Cancer
|
|
GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)) .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W134005
-
|
Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate
|
Chelators
|
|
Mg(Ⅱ)-EDTA disodium tetrahydrate is a reversible non-covalent activator of fructose diphosphatase (Km=0.9 μM). Mg(Ⅱ)-EDTA disodium tetrahydrate synergistically activates fructose diphosphatase with free Mg 2+, promotes the hydrolysis of fructose-1,6-bisphosphate at pH≤8, and plays a role in enhancing the activity of key enzymes in gluconeogenesis .
|
-
- HY-134816
-
|
|
Carbohydrates
|
|
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W141881
-
|
|
Biochemical Assay Reagents
HSV
|
Infection
|
|
N-lauroylsarcosine is an anionic surfactant. N-lauroylsarcosine has antiviral activity against HSV-2 strain 333 and HSV-1 strain F. N-lauroylsarcosine synergistically increases skin permeability with 25-50% ethanol. N-lauroylsarcosine can be used to study HSV-2 infection .
|
-
- HY-P5589
-
|
PlnA
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
Inflammation/Immunology
|
|
Plantaricin A is an antimicrobial peptide that can be derived from Lactobacillus plantarum. Plantaricin A has a synergistic effect with Ciprofloxacin. Plantaricin A shows anti-microbial activity. Plantaricin A increases the membrane potential of S. aureus and the level of intracellular ROS. Plantaricin A inhibits the function of the efflux pump by binding it and altering the structure of MepA, NorA, and LmrS. Plantaricin A significantly relieves inflammation, and promotes wound healing. Plantaricin A permeabilizes cancerous rat pituitary cells [1][2].
|
-
- HY-P4032
-
|
|
HCV
|
Inflammation/Immunology
|
|
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
|
-
- HY-12403A
-
|
TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
|
-
- HY-12403
-
|
TXA127; Angiotensin (1-7); Ang-(1-7)
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-12403R
-
|
|
Angiotensin Receptor
Angiotensin-converting Enzyme (ACE)
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
|
-
- HY-P11040
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Peptide P2.2, a non-ribosomal peptide, is an antimicrobial peptide. Peptide P2.2 has potent antibacterial activity with MIC50s of 4 and 32 μM for V. parahaemolyticus and V. alginolyticus, respectively. Peptide P2.2 increases synergistic antibacterial effects with antibiotics (such as Ofloxacin (HY-B0125) and Linezolid (HY-10394)) with negligible hemolytic activity. Peptide P2.2 disrupts bacterial membranes and increases permeability by modulating proteins involved in the type VI and III secretion systems. Peptide P2.2 can be used for bacterial infections research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99100
-
|
CTL-002
|
TGF-beta/Smad
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P99100A
-
|
CLT-002 (Powder)
|
TGF-beta/Smad
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991510
-
|
|
TNF Receptor
|
Cancer
|
|
CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
|
Classification |
-
- HY-19476
-
|
|
|
Alkynes
|
|
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-160067
-
|
|
|
Aptamers
|
|
T18.3 aptamer sodium is an anticoagulant RNA aptamer targeting FV/Va and eliminates the interaction of FV/FVa with phospholipid membranes. T18.3 aptamer sodium exhibits clinically relevant anticoagulant activity in plasma and whole blood and acts synergistically with low molecular weight heparin. The anticoagulant activity of T18.3 aptamer sodium is effectively and rapidly reversed by protamine sulfate .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
